The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Mesa Discusses Pacritinib's Potential in Myelofibrosis
June 11th 2015Lead PERSIST-1 author Ruben A. Mesa, MD, deputy director of the Mayo Clinic Cancer Center in Scottsdale, Arizona, discussed the trial's results and pacritinib's potential to change the treatment paradigm for patients with myelofibrosis.
Precision Medicine Collaboration to Increase Options for Cancer Patients
June 4th 2015Baylor Research Institute (BRI) at Dallas and the Translational Genomics Research Institute in Phoenix, AZ, today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers.
FDA Schedules ODAC Meeting for Necitumumab in NSCLC
June 3rd 2015The FDA has scheduled an ODAC advisory hearing to discuss the biologics license application for necitumumab in combination with gemcitabine and cisplatin as a first-line treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer.
FDA Grants Priority Review to Pembrolizumab in Lung Cancer
June 2nd 2015The FDA has assigned a priority review designation to the PD-1 inhibitor pembrolizumab as a treatment for patients with advanced NSCLC across all histologies whose disease has progressed on or after platinum-containing chemotherapy, as well as a targeted agent in EGFR- or ALK-positive patients.
OncLive's 2015 Giants of Cancer Care Awards Announced
May 30th 2015Twelve of the nation's leading oncology physicians, researchers and academicians were recognized by their peers as the 2015 Giants of Cancer Care at a ceremony hosted by OncLive at the Chicago Illuminating Company last night. The awardees included medical pioneers selected by a panel of eminent oncologists for landmark achievements in translational research, gene therapy, immuno-oncology and other groundbreaking work that has changed the course of cancer treatment.
OncLive's 2015 Giants of Cancer Care Awards Announced Today
May 29th 2015OncLive proudly announces the 2015 Giants of Cancer Care, a dozen medical pioneers recognized by a panel of eminent oncologists for landmark achievements that have changed the course of cancer treatment. Honorees will be introduced and celebrated at the 3rd Annual Giants of Cancer Care Award Ceremony, held 8:30-11:00 p.m. CDT at The Chicago Illuminating Company.
As FDA Considers Approval, Weber Discusses Adjuvant Ipilimumab in Melanoma
May 26th 2015To better understand the impact of the EORTC 18071 trial, the chances of approval in the adjuvant setting, and the challenges concerning the dosage and toxicity with ipilimumab, OncLive spoke with the study's lead author Jeffrey S. Weber, MD, PhD.
Optimization of Melanoma Treatment Advances Remains a Work in Progress
May 19th 2015Immunotherapies and targeted therapies have led to significant strides in the treatment of patients with melanoma. However, determining which therapies are best for which patients and how to treat patients who don't respond or stop responding to these new therapies is still a challenge. For further insight on optimizing the recent treatment breakthroughs in melanoma, OncLive spoke with Alan Bryce, MD, medical director of the Genomic Oncology Clinic at Mayo Clinic.
Study Offers Solution for HER2 Resistance in Breast Cancer
May 19th 2015By targeting the HER2 protein's ability to transform cells, therapies such as trastuzumab (Herceptin) and pertuzumab (Perjeta) have significantly extended the survival of women with HER2-positive breast cancer. However, major treatment challenges still remain for this breast cancer subtype, according to Ruth Lupu, PhD, professor of Laboratory Medicine and Pathology at Mayo Clinic.